文献速递急性肾损伤血液净化与透析

尿液CCL14预测持续性重度急性肾损伤的验证研究

Validation of Urinary C-C Motif Chemokine Ligand 14 for Persistent Severe Acute Kidney Injury Using Clinical Adjudication.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-09-16

Diamond研究为多中心前瞻性观察研究,纳入476例ICU内36小时内KDIGO 2-3期AKI患者,用临床裁定委员会判定持续性重度AKI(PS-AKI)。尿液CCL14预测PS-AKI的AUC为0.70,1.3 ng/ml截断点敏感性78.1%、特异性49.8%;CCL14每升高1 ng/ml,启动肾脏替代治疗率增加6%。

要点

  • ICU 2-3期AKI患者中,尿CCL14可识别PS-AKI高危者,AUC为0.70。
  • 1.3 ng/ml截断点敏感性78.1%、特异性49.8%;13 ng/ml截断点敏感性24.5%、特异性93.5%。
  • CCL14每升高1 ng/ml,启动KRT率增加6%;>13 ng/ml者KRT风险HR 5.70。

核心结论

  • 在ICU 2或3期AKI患者中,尿CCL14与PS-AKI、启动KRT及死亡风险升高相关。
  • 未来可借助CCL14富集PS-AKI高风险人群以开展AKI治疗研究。

研究设计与样本

  • Diamond研究为多中心前瞻性观察研究,纳入ICU内36小时内KDIGO 2或3期AKI患者476例并检测尿CCL14。
  • 主要终点为临床裁定委员会(3名AKI领域肾内科医生)判定的PS-AKI,即持续≥72小时的3期AKI。

主要发现

  • 151例(32%)被裁定为PS-AKI;入组时PS-AKI患者APACHE III评分更高且3期AKI更多(P<0.002)。
  • 95例(20%)接受KRT,98例(21%)死亡,155例(33%)30天内接受KRT和/或死亡。
  • CCL14预测PS-AKI的AUC(95%CI)为0.70(0.65-0.76)。
  • 1.3 ng/ml截断点敏感性78.1%(70.9%-84.0%)、特异性49.8%(44.4%-55.3%);13 ng/ml截断点敏感性24.5%、特异性93.5%。
  • CCL14每升高1 ng/ml启动KRT率增加6%;>13 ng/ml相对≤1.3 ng/ml的KRT风险HR 5.70(3.22-10.11),KRT或死亡HR 3.50(2.19-5.60),P<0.001。

关键数值与推荐

  • PS-AKI定义为3期AKI持续≥72小时,由3名肾内科医生组成的临床裁定委员会判定。
  • CCL14截断点采用既往建立的1.3 ng/ml与13 ng/ml。

临床怎么用

  • 对ICU 2-3期AKI患者可检测尿CCL14,辅助识别PS-AKI及KRT高风险者。
  • 1.3 ng/ml适合筛查高敏感,13 ng/ml高特异有助于确认高风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: In intensive care unit patients with stage ≥2 AKI, urinary C-C motif chemokine ligand 14 identifies those with a higher risk of stage 3 AKI that lasts 3 days, need for KRT, or death. The sensitivity and specificity of urinary C-C motif chemokine ligand 14 were 78.1% and 49.8% at the 1.3 ng/ml cutoff and 24.5% and 93.5% at the 13 ng/ml cutoff, respectively. For every 1 ng/ml increase in C-C motif chemokine ligand 14, there was a 6% higher rate of KRT initiation, but no increased risk of death. BACKGROUND: Urinary C-C motif chemokine ligand 14 (CCL14) has been demonstrated to prognosticate persistent severe AKI (PS-AKI) in patients with established AKI. We sought to validate the performance of CCL14 among intensive care unit (ICU) patients, at previously established cutoffs of 1.3 and 13 ng/ml. METHODS: The Diamond Study was a multicenter, prospective, observational study of ICU patients with Kidney Disease Improving Global Outcomes stage 2 or 3 AKI within the last 36 hours. Urine was collected at enrollment for CCL14 measurement. The primary study end point was the development of PS-AKI (stage 3, lasting for ≥72 hours) as determined by a clinical adjudication committee consisting of 3 nephrologists with expertise in AKI. RESULTS: We enrolled 476 patients with CCL14 measurements and 151 (32%) were adjudicated to have PS-AKI. At enrollment, PS-AKI patients had higher Acute Physiology and Chronic Health Evaluation III scores and more stage 3 AKI ( P < 0.002 for both). Ninety-five (20%) patients received KRT, 98 (21%) died, and 155 (33%) received KRT and/or died within 30 days. The area under the receiver operating characteristic curve (95% confidence interval) for CCL14's prediction of PS-AKI was 0.70 (0.65 to 0.76). The sensitivity at the 1.3 ng/ml cutoff was 78.1% (70.9% to 84.0%), whereas the specificity was 49.8% (44.4% to 55.3%). For every 1 ng/ml increase in CCL14, there was a 6% higher rate of KRT initiation; with values above 13 ng/ml having a hazard ratio (95% confidence interval) of 5.70 (3.22 to 10.11) for need for KRT and 3.50 (2.19 to 5.60) for need for KRT or death relative to values ≤1.3 ng/ml ( P < 0.001 for all). CONCLUSIONS: In ICU patients with stage 2 or 3 AKI, urinary CCL14 is associated with a higher risk of PS-AKI, including KRT initiation and death. Future efforts to treat AKI could be enriched using CCL14 to target those at a high risk of PS-AKI. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT04785391 .

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Kampf JP, Al-Khafaji A, Arora S, et al. Validation of Urinary C-C Motif Chemokine Ligand 14 for Persistent Severe Acute Kidney Injury Using Clinical Adjudication. Clin J Am Soc Nephrol. 2026. PMID: 42747895. doi:10.2215/CJN.0000001212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。